Internal Server Error

List of Pfizer's Acquisitions

lockFilter this list
Pfizer has made a total of 41 acquisitions. The company has invested across 22 distinct Oncology, Diversified Pharmaceuticals, and Infectious Diseases sectors in 5 countries, including United States, United Kingdom, and Canada. Peak activity occurred in 2008 and 2007, with 4 acquisitions each, and 2022, with 3 acquisitions. Between 2020 and 2025, the average number of acquisitions per year was 1.6, with 0 acquisitions completed in the current calendar year. Its most recent acquisition is Metsera, a biopharmaceutical company founded in 2022 and based in New York City that focuses on medicines for obesity and metabolic diseases. This transaction was finalized in September 2025.

Here's the year on year acquisition history of Pfizer:

Year on year acquisition history of Pfizer20252023202220212019Acquisitions Round Date (Yearly)01234
  • Number of Total Acquisitions
Year
# Acquisitions
2025
1
2023
1
2022
3
2021
3
2019
2
2016
3
2015
2
2014
2
2012
3
2011
2
2010
3
2008
4
2007
4
2006
2
2005
3
2004
1
2003
1
2002
1

Recent acquisitions by Pfizer

Pfizer's most recent acquisition - Metsera is a Biopharmaceutical company focusing on medicines for obesity and metabolic diseases, founded in 2022 and located in New York City. Pfizer acquired it in September 2025 for a price of $*****.

Here is the list of all acquisitions by Pfizer sorted by the latest acquisition date:

Acquired on
Acquired Company
Acquisition Price
Facilitators
Stake Acquired
Acquisition Multiple
Sep 22, 2025
ly{r
vldl
80
529
Mar 13, 2023
iwze
kgix
90
580
Aug 08, 2022
lkmu
bthr
13
701
May 10, 2022
dilp
bhlt
72
331
Apr 07, 2022
wvsd
ytin
70
197

View the full list of acquisitions

Sign Up for Free

News related to Pfizer's acquisitions

lockFilter this list

Media has covered Pfizer for a total of 258 events in the last 1 year, 48 of them have been about acquisition activity.

View More Pfizer Recent News

FAQs about Acquisitions by Pfizer

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford